key: cord-0981069-rugfygar
authors: Desai, Parth V.; Krepostman, Nicolas; Collins, Matthew; De Sirkar, Sovik; Hinkleman, Alexa; Walsh, Kevin; Fareed, Jawed; Darki, Amir
title: Neurological Complications of Pulmonary Embolism: a Literature Review
date: 2021-10-20
journal: Curr Neurol Neurosci Rep
DOI: 10.1007/s11910-021-01145-8
sha: bb672b855194bf94dc4d71ad97ff073aa88d9616
doc_id: 981069
cord_uid: rugfygar

PURPOSE OF REVIEW: The present review discusses in-depth about neurological complications following acute venous thromboembolism (VTE). RECENT FINDINGS: Intracranial hemorrhage, acute ischemic cerebrovascular events, and VTE in brain tumors are described as central nervous system (CNS) complications of PE, while peripheral neuropathy and neuropathic pain are reported as peripheral nervous system (PNS) sequelae of PE. Syncope and seizure are illustrated as atypical neurological presentations of PE. SUMMARY: Mounting evidence suggests higher risk of venous thromboembolism (VTE) in patients with neurological diseases, but data on reverse, i.e., neurological sequelae following VTE, is underexplored. The present review is an attempt to explore some of the latter issues categorized into CNS, PNS, and atypical complications following VTE.

Venous thromboembolism (VTE), a term collectively referred for deep vein thrombosis (DVT) and pulmonary embolism (PE) is often underdiagnosed and potentially life threatening. This preventable medical condition is the

DVTs are classified based on location and etiology. Lower limb DVT with thrombi proximal to the popliteal trifurcation is labeled as proximal whereas below is identified as distal DVT. Upper limb DVT is far less common than lower extremity but still account for 10% of DVTs, predominantly related to indwelling central venous catheters and cardiac leads from pacemakers and defibrillators [6] . The etiology of DVT as provoked (with underlying trigger) versus unprovoked (without an identifiable trigger) and temporary (reversible trigger) versus permanent (irreversible trigger) [7] helps guide duration of treatment and risk of recurrence. [8] . Although majority of distal DVT spontaneously resolve with minimal symptoms, significant morbidity can be caused by thrombi extending into popliteal, femoral, and other proximal veins [9, 10] .

Common complications of DVT include post-thrombotic syndrome (PTS), PE, and sudden death [11] . If left untreated, there is a 50% chance that proximal DVT will cause symptomatic PE within 3 months [10, 12] . PTS occurs in about 30-50% DVT patients which sometimes result in lifelong limb pain, swelling, heaviness, edema, telangiectasias, lipodermatosclerosis, and leg ulcers [13] [14] [15] . In patients with proximal DVTs, 30-40% are likely to develop PE, while 70% of patients with PEs have concomitant DVT [16] . Estimate suggests that 10-30% people die of VTE within 1 month of diagnosis with about a quarter of people presenting as sudden death [2] . Data also suggests about one third (33%) of the patients with VTE would have recurrence within 10 years of initial diagnosis [2] .

Acute PE is classified per the American Heart Association (AHA) and European Society of Cardiology (ESC) guidelines into massive, sub-massive (high/intermediate risk), and low risk (Table 1 ) based on the hemodynamic stability and end-organ damage (elevated cardiac biomarkers and right ventricular strain) [17, 18] . This classification helps to stratify risk of decompensation and guides in management decisions [17] [18] [19] . Pulmonary Embolism Severity Index (PESI) and simplified PESI (sPESI) are incorporated into the ESC guidelines for further risk stratification [20, 21] .

While acute massive PE can cause immediate cardiorespiratory failure resulting in death, longstanding PE can cause chronic thromboembolic pulmonary hypertension Table 1 Criteria for risk-stratification of acute pulmonary embolism Abbreviations: ESC -European Society of Cardiology, AHA -American Heart Association Page 3 of 15 59 (CTEPH) and eventually right heart failure [22] . Given that all forms of VTE will need some form of anticoagulation, hemorrhagic complications in the forms of gastrointestinal, central nervous system (CNS), genitourinary, pulmonary, and other vascular bleeding are not uncommon [9] . Between 2 and 5% of patients with VTE could experience major bleeding within 3 months [23].

Neurological complications following VTE can be divided into three groups ( Fig. 1 Streptokinase, urokinase, and alteplase are currently the only FDA-approved thrombolytics for PE [32] . These agents work by activating plasminogen, causing clot lysis and ultimately improving pulmonary artery pressure and pulmonary perfusion [32]. Thrombolytic therapy has been shown to improve mortality in high-risk population and prevent the development of CTEPH [33] [34] [35] [36] . However, improvement in these outcomes comes at the cost of increased risk of ICH (Table 3) , with a reported incidence rate of 1-3% depending on agent used [55] . Absolute contraindications for thrombolytics include structural intracranial disease, previous ICH, ischemic stroke within 3 months, active bleeding, recent brain or spinal surgery, recent head trauma or brain injury, or bleeding diathesis [18] . A meta-analysis of 26 trials including 2784 patients by Izcovich et al. showed an increase in ICH (RR 3.17, 95% CI 1.19-8.41) with the use of thrombolytics compared to controls [56] . The largest trial evaluating the use of full dose systemic tPA for acute submassive PE was the PEITHO trial-a multicenter, double-blinded study randomizing 1005 patients with submassive PE to either placebo vs weight-based tenecteplase [57] . The trial demonstrated a significant reduction in the primary endpoint of death and hemodynamic collapse (2.6%). However, the fibrinolytic treatment was associated with an unacceptable 2.0% rate of hemorrhage stroke and 6.3% rate of major extra cranial hemorrhage. As bleeding complications from thrombolytics are thought to be dose-dependent, various studies investigating optimal dosing have suggested lower doses are equally efficacious with less bleeding risk [58] . Reduced dose thrombolytics are potentially beneficial in high-risk populations such as elderly, pregnant, surgical candidates, and patients weighing less than 65 kg [59] . A meta-analysis of five trials consisting of 440 patients conducted by Zhang et al. compared low dose rt-PA (50 mg over 2 hours) to standard dose (100 mg over 2 hours) which showed no statistical difference in recurrent PE or all case mortality with few major bleeding events [32, 60] . Additionally, the MOPPET trial randomized 121 patients with submassive PE to either low dose alteplase (0.5 mg/kg, max 50 mg) or anticoagulation alone and found a reduced incidence of pulmonary hypertension and recurrent PE in the thrombolytic group with no bleeding events reported in either group [43] .

In addition to low-dose thrombolytics, catheter-directed thrombolysis (CDT) has also been studied to reduce hemorrhagic risk in patients with acute PE. The goal of CDT is to locally deliver thrombolytics to the site of thrombus with reduced bleeding risk compared to systemic thrombolytics [61] . The ideal candidate is stable enough to tolerate a prolonged infusion and has a proximal thrombus [40, 62, 63•] . Three prospective trials ULTIMA, SEATTLE II, and PERFECT have shown that CDT can be efficacious with relatively low bleeding risk [63•] . The ULTIMA trial randomized 59 patients to CDT plus heparin vs heparin alone and found improvement in RV/LV ratio with no major bleeding in the CDT group [40] . SEATTLE II was a prospective single-arm trial that included 150 patients treated with CDT and found statistical improvement in hemodynamic parameters, with 17 major bleeds but no ICH [62] . The PER-FECT registry examined 101 patients with catheter-directed mechanical thrombectomy and/or CDT, with main outcome being composite of hemodynamic parameters and survival to hospital discharge [64] . Their results showed improvement in these measures without major bleeding events, including ICH [64] . While these studies have limitations, they provide evidence that CDT can be safe and efficacious treatment option for acute PE in appropriate patients [63•] . Given the complexity in selecting therapy for VTE patients, multiple bleeding stratification scores have been developed. Scores such as REITE score, outpatient bleeding risk index (OBRI), the Dutch score, and Kuijer scores have all been trialed [65] . The HAS-BLED score, a bleeding stratification tool used for anticoagulation in atrial fibrillation, has also recently been studied in the VTE population and found to have predictive validity. A large retrospective study of 132,280 VTE patients found that patients with scores greater than four were at higher risk for bleeding events [66] .

Compared to hemorrhagic stroke, less is known about subsequent arterial events such as ischemic stroke following VTE. One of the earliest known associations between VTE and atherosclerotic disease is that patients with unprovoked DVTs are more likely to have asymptomatic carotid disease [67] . While the mechanism for this association remains unclear, some contribution is likely due to shared risk factors including obesity, diabetes, and dyslipidemia [68, 69] 

Patent foramen ovale (PFO) is a persistent fetal communication between the right and left atria due to failure of primum and secundum atrial septa to fuse postpartum. Although the prevalence of PFO is ~25% in the general population, the prevalence increases to nearly 50% in young patients (<55 years) who present with cryptogenic ischemic stroke [71•] . Under certain hemodynamic conditions with right-to-left atrial shunt (RLS) (e.g., PFO, atrial septal defect (ASD) or atrial septal aneurysm (ASA)) blood and bloodborne products migrate from venous circulation to arterial system leading to paradoxical embolism as reported previously [72] [73] [74] .

Concomitant PE and acute ischemic stroke is a rare event but has been described in various case reports and series [75] [76] [77] [78] 79 Several prospective and retrospective studies have linked the presence of PFO with increased prevalence of ischemic stroke (clinical or silent) in the patients with acute VTE [82•, 84-86] . Under the physiological conditions, the flap-like PFO defect is passively closed due to left to right pressure gradient. However, this gradient may be reversed during acute PE which results in RLS [87] . In patients with highrisk PE, acute rise in pulmonary hypertension and resultant right heart strain leads to profound and persistent RLS providing a passage for venous thrombi to travel across PFO. In a large prospective study, Le Moigne and colleagues quantified the prevalence of subsequent stroke in 361 consecutive patients presenting with symptomatic PE with and without PFO [72] . The study concluded that presence of PFO was an independent risk factor due to a fourfold increased risk of ischemic stroke. Of note, authors also noticed higher risk of stroke when ASA was present. It is postulated that septal excursions due to ASA allows more flow through PFO leading to increased risk of thrombi migration [88, 89] . Due to such a high risk of stroke, systematic screening of PFO is essential in this population [90••] . Although TEE is considered a gold standard test to diagnose PFO [91] , according to 2016 American society of echocardiography guidelines [91] , screening with either TTE or TEE with agitated saline contrast has comparable accuracy [92, 93] . However, in either scenario-repeated provocative Valsalva maneuver is crucial to improve accuracy of detecting PFO [94] .

Among patients with PE and/or DVT and confirmed PFO, there should be higher suspicion and scrutiny for silent ischemic events, mainly with diffusionweighted brain MRI [95••] . Clergeau et. al [86] studied 60 consecutive patients admitted with PE. All patients underwent clinical neurological assessment followed by diffusion-weighted brain MRI and contrast TTE on the day after admission. PFO was diagnosed in 15/60 (25%) patients. The frequency of silent brain infarcts was significantly higher in patients with PFO compared to non-PFO (5/15 versus 1/45, p=0.003) group. At times, the patterns of ischemic brain lesions on diffusionweighted MRI helped to distinguish between PFOstroke compared to other etiology of embolic stroke. In a retrospective qualitative comparison study of 117 PFOstroke patients to 358 patients with atrial fibrillationstroke (AF-stroke), Kim and colleagues [96] showed that a PFO-stroke usually appears as a single cortical or multiple small (<15 mm) scattered ischemic lesions in the vertebrobasilar circulation without any visible vessel occlusion on angiography.

Cryptogenic stroke (CS) is thought to comprise of ~25% of all acute ischemic strokes [97] . Although a prospective study showed that PFO is not an independent risk factor for future cerebrovascular events in general population [98] , various studies have demonstrated a higher prevalence of PFO in CS in all age groups despite adjudicating for known risk factors for stroke [99] [100] [101] . Ozdemir et al. described that significant history of VTE, migraine, recent prolonged travel, sleep apnea, or a Valsalva maneuver preceding the event are established clinical clues indicating paradoxical embolism among patients with CS [102] . As such, a low threshold should exist to look for VTE in patients with CS linked to PFO when suspicion is high [95••] . However, the absence of DVT on lower extremity ultrasound after CS does not necessarily rule out venous origin of source of embolism as a small clot might have dislodged or dissolved [103] . Mounting evidence suggests that PFO device closure is more effective than medical therapy alone for secondary prevention of suspected embolic stroke of uncertain etiology (ESUS) in select patients aged less than 60 years with large PFO with or without associated ASA [104] [105] [106] . According to a 2018 meta-analysis of 4 high-quality RCTs enrolling 2531 patients [107•] , PFO closure led to 60% reduction in recurrent ischemic strokes over 3-6 years follow-up period.

May-Thurner syndrome (MTS) (also known as iliac vein compression syndrome or Cockett's syndrome) is a rare anatomical variant where right iliac artery compresses left iliac vein against the lumbar spine leading to increased risk of left leg DVT [108, 109•] . In a retrospective study of 470 CS patients undergoing PFO closure at a single center, Kiernan et al. found 30/470 (6.3%) patients had MTS on MR venography of pelvis. While majority of them were women (80%), 40% had thrombophilia and 54% women were taking birth-control pills [110] . In another retrospective study of 214 patients with CS comparing 50 controls, not only prevalence of MTS and PFO was significant higher in CS patients (p=0.0001, p=0.0023, respectively), but compression of left iliac vein was also significantly greater (32% vs 13%, p< 0.00001) [111] .

Severe acute respiratory syndrome coronavirus (SARs-CoV-2) has resulted in a global pandemic of COVID-19, with more than 130 million cases and 2.8 million deaths by the end of March 2021 [112] . Although predominantly known as a respiratory illness, its inflammatory response predisposes to thrombotic complications such as MI, VTE, and ischemic stroke [113] . The risk of VTE in patients with COVID-19 admitted to the ICU has been estimated between 20 and 40% [114] . Additionally, a systematic review of 55,176 COVID-19 patients reported an average incidence of stroke as 1.74% (95% CI: 1.09-2.51%), with an average stroke mortality of 31.76% (95% CI: 17.77-47.31%) [115•] . Proposed mechanisms for ischemic strokes in this population includes systemic inflammatory response, comorbid cardiovascular conditions, as well as direct invasion of the brain parenchyma by SARS-COV-2 [115•, 116] .

Cancer is a known risk factor for VTE with a sevenfold increase incidence of VTE associated with malignancy [117] . The underlying mechanism for this involves a complex array of molecular interactions driven by the expression of hemostatic proteins, adhesion molecules, inflammatory cytokines, proangiogenic factors, microparticles by tumor and host cells, and even vascular compression from tumor burden [118, 119] . Thrombotic sequelae of cancer can also manifest in other ways, including a nearly twofold increase in ischemic stroke incidence [120] , as well as disseminated intravascular coagulation (DIC) and Trousseau syndrome (TS). TS is the manifestation of migratory thrombophlebitis in the setting of malignancy. Though the exact mechanism remains unclear, it is often seen in mucin-producing cancers such as gastric cancer. Embolic stroke diagnosed in malignancy, especially when occurring in disparate cerebral regions, should raise suspicion for TS [121•, 122-124] . Cerebral infarction from TS has been documented across a wide spectrum of malignancies from benign adenomyosis to thyroid cancer [121•, 125] .

One-year cumulative incidence of VTE following malignancy is varied after solid tumors-brain (6.9%), pancreas (5.3%), stomach (4.5%), and lung (2.4%)-and hematological malignancies, acute myelogenous leukemia (3.7%) and chronic myelogenous leukemia (1.5%) [120, 126] . Patients with metastases have a higher risk compared to those without (OR 19.8) [117] . Depending on the type of CNS malignancy, annual VTE incidence ranges from 0.5 to 20% [127] . Glioblastoma is the CNS tumor with highest incidence of VTE (15.7%), while meningioma rarely leads to VTE (<1%) [128] . Other tumor-related risk factors leading to increased risk of VTE include larger size, intraluminal thrombosis, IDH1 wild-type, high soluble P selectin levels, and podoplanin expression [129••, 130, 131] , as well as subtotal surgical resection, use of corticosteroids, anti-VEGF therapy, leukocytosis, and thrombocytopenia [128, 132, 133] . Notably, patients with malignant gliomas who develop VTE within the first 2 years have a 30% higher risk of death [134] .

Syncope is not a classical presentation of PE, but not an uncommon one with an estimated incidence of 13% in all patients with PE [135] . It can be explained by three possible mechanisms [135] . (1) Occlusion of the pulmonary vascular tree causing right ventricular failure and impaired left ventricular filling, leading to a reduction in cardiac output, arterial hypotension, cerebral hypoperfusion, and, ultimately, loss of consciousness. (2) Right ventricular overload and dilatation predisposing to a variety of arrhythmias, including ventricular tachycardia or ventricular fibrillation. In patients with pre-existing conduction system disease, the development of a right bundle branch block commonly seen in acute pulmonary embolism can cause complete AV block and other brady-dysrhythmias.

(3) Finally, PE may trigger a neurogenic syncope via a vasovagal reflex. The Bezold-Jarisch reflex of bradycardia and coronary vasodilation can lead to profound systemic hypotension, cerebral hypoperfusion, and syncope in acute RV ischemia [136, 137] Among all presentations of PE, syncope portends a worse prognosis [138] [139] [140] [141] [142] [143] [144] [145] , though some contradictory studies show no difference in mortality [135, [145] [146] [147] . In the International Cooperative Pulmonary Embolism Registry, the 3-month mortality rate of patients with syncope was 26.8% compared to 17% in the non-syncope PE population [148] . Syncope was associated with a higher prevalence of hemodynamic instability (OR 3.5), echocardiographic signs of RV dysfunction (OR 2.1), 30-day all-cause mortality (OR 1.73), and PE-related 30-day adverse outcomes (OR 2.0) [149••] . Conversely, in patients with syncope, prevalence of PE is around 8-17% [67, 135, 146, [150] [151] [152] . In most studies, syncope led to a diagnosis of acute PE in the setting of other symptoms like chest pain, dyspnea, tachycardia, or tachypnea [153] . Certain factors which have been shown to predict syncope in PE patients are larger clot burden [154, 155] , central location of PE [147, 156] , and saddle embolism [147] .

PE can present heterogeneously, with seizures being one of the rarest and most interesting clinical manifestations. Mostly described in the literature as case reports [157] [158] [159] [160] , acute PE presenting with new onset seizures is believed to occur in less than 1% of PE cases [157] . Potential pathophysiology includes hypoxia-driven cardiogenic seizures, with right ventricular failure and decreased cardiac output leading to transient global cerebral hypoperfusion [158] . A literature review by Zuin et al. [161••] identified 16 case reports where focal and generalized seizures were identified in 37.5% and 50% of PE cases, respectively, with the remainder lacking sufficient data for diagnosis. Neurologic comorbidities such as history of childhood epilepsy, stroke, and syncope were identified in 25% of the patients. Eleven of the 16 patients were hemodynamically stable on admission, with systemic thrombolysis eventually being used in 5 cases. The reported morality rate was 54.5%, with diagnosis of PE retrospectively made at autopsy in 25% of patients. The high mortality rate is largely attributed to delay in diagnosis, a challenge also described in previous case reports [160, 162, 163] . Clinicians have the difficult task of recognizing underlying PE in the presentation of seizure while also ruling out concomitant ICH prior to starting treatment [161••] . Further investigation needs to be aimed at identifying the predisposing risk factors, clinical presentation, and treatment for these challenging cases.

VTE, and the treatment of VTE, can affect the PNS in a number of ways. The most common mechanism of peripheral nerve injury in connection with VTE is a post-thrombotic syndrome (PTS). Up to half of all patients with acute proximal DVT will develop PTS, and 5-10% will develop severe symptoms [164] . The mechanism of neuropathic pain associated with PTS appears to be a combination of both inflammation surrounding affected nerves and possibly a demyelinating process [165] . While the treatment of PTS is centered on symptomatic management of the neuropathic pain, prevention relies on the use of elastic compression stockings to reduce venous hypertension and exercise [164] .

In addition to PTS, peripheral neuropathy from VTE can occur, although rarely, due to direct entrapment neuropathy from DVT or due to VTE treatment. Femoral neuropathy can develop as a consequence of VTE through retroperitoneal hematoma from anticoagulation [166] . Moreover, direct damage to the femoral nerve via transfemoral approaches in CDT or mechanical thrombectomy is possible with an incidence of 1.5% [167] . VTE of the crural veins causing entrapment neuropathy has been described in case reports of peroneal neuropathy resulting in foot drop [168, 169] . In the upper extremity, brachial vein DVT has been reported as a cause of cubital tunnel syndrome. [170] . Median nerve entrapment neuropathy secondary to spontaneous hemorrhage into the carpal tunnel following anticoagulation for VTE has also been reported [171] .

VTE is known to have heterogeneous presentations leading to morbid or fatal outcomes. While cardiovascular complications of DVT/PE are well-known, neurologic consequences of VTE are mainly known for ICH which is indirectly linked to the treatment of VTE. In addition to ICH, this review has described the other potential yet underdiagnosed complications of VTE such as acute ischemic strokes, risk of CS in the setting of right-to-left intracardiac shunts, and some of the peripheral entrapment neuropathies due to DVT and post-thrombotic syndrome. The association between VTE and neurologic complications is complex, and further investigation is needed to guide management. 

Global burden of thrombosis: Epidemiologic aspects

Venous thromboembolism: a public health concern

The economic burden of incident venous thromboembolism in the United States: A review of estimated attributable healthcare costs

Virchow and his triad: a question of attribution

Ischemic Stroke and Risk of Venous Thromboembolism in the General Population: The Tromsø Study

Deep-vein thrombosis of the upper extremities

Categorization of patients as having provoked or unprovoked venous thromboembolism: guidance from the SSC of ISTH

Venous thromboembolism: classification, risk factors, diagnosis, and management

Hemorrhagic complications of anticoagulant treatment: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy

Deep vein thrombosis--risks and diagnosis

Diagnosis and treatment of deep-vein thrombosis

Natural history of venous thromboembolism

Management of venous thromboembolism: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians

The post thrombotic syndrome

thromboembolism: a randomized, multicenter, controlled trial

Moderate pulmonary embolism treated with thrombolysis (from the "mOPETT" Trial)

Hemodynamic effects of double bolus reteplase versus alteplase infusion in massive pulmonary embolism

Alteplase versus heparin in acute pulmonary embolism: randomised trial assessing right-ventricular function and pulmonary perfusion

Effects of intravenous urokinase versus alteplase on total pulmonary resistance in acute massive pulmonary embolism: a European multicenter double-blind trial. The European Cooperative Study Group for Pulmonary Embolism

Management Strategies and Prognosis of Pulmonary Embolism-3 Trial Investigators. Heparin plus alteplase compared with heparin alone in patients with submassive pulmonary embolism

Time course of platelet aggregation during thrombolytic treatment of massive pulmonary embolism

Six-month echocardiographic study in patients with submassive pulmonary embolism and right ventricle dysfunction: comparison of thrombolysis with heparin

Thrombolytic therapy in the treatment of acute sub-massive pulmonary embolism: a prospective observational study

Recombinant tissue-type plasminogen activator versus a novel dosing regimen of urokinase in acute pulmonary embolism: a randomized controlled multicenter trial

Incidence of arterial cardiovascular events after venous thromboembolism: A systematic review and a meta-analysis

Fibrinolysis for patients with intermediaterisk pulmonary embolism

Treatment of submassive pulmonary embolism with tenecteplase or placebo: cardiopulmonary outcomes at 3 months: multicenter double-blind, placebo-controlled randomized trial

Impact of Vena Cava Filters on in-Hospital case fatality rate from pulmonary embolism

Thrombolytics for venous thromboembolic events: A systematic review with meta-analysis

Fibrinolysis for Patients with Intermediate-Risk Pulmonary Embolism

Thrombolysis compared with heparin for the initial treatment of pulmonary embolism: A meta-analysis of the randomized controlled trials

Low-Dose Systemic Alteplase (tPA) for the Treatment of Pulmonary Embolism. Ann Pharmacother

Lower dosage of recombinant tissue-type plasminogen activator (rt-PA) in the treatment of acute pulmonary embolism: A systematic review and meta-analysis

Interventional Treatment of Pulmonary Embolism

Single-Arm, Multicenter Trial of Ultrasound-Facilitated, Catheter-Directed, Low-Dose Fibrinolysis for Acute Massive and Submassive Pulmonary Embolism: The SEATTLE II Study

This review describes clinical presentation of submissive PE and role for catheter directed thrombolysis

Pulmonary embolism response to fragmentation, embolectomy, and catheter thrombolysis (PERFECT): Initial results from a prospective multicenter registry

Prospective, multicenter validation of prediction scores for major bleeding in elderly patients with venous thromboembolism

Risk stratification for bleeding complications in patients with venous thromboembolism: Application of the HAS-BLED bleeding score during the first 6 months of anticoagulant treatment

An Association between Atherosclerosis and Venous Thrombosis

Venous thromboembolism and subsequent hospitalisation due cardiovascular events: a 20-year cohort study

Cardiovascular risk factors and venous thromboembolism: A meta-analysis. Circulation

Subsequent arterial ischemic events in patients receiving anticoagulant therapy for venous thromboembolism

This review described the prevalence of PFO in general population and stroke patients and emphasized that it should not be underestimated

Acute Limb Ischemia Secondary to Patent Foramen Ovale-Mediated Paradoxical Embolism: A Case Report and Systematic Review of the Literature

Pulmonary embolism and infarction with a paradoxical thrombus visualised in both atria

Case report: Thrombus in transit-a cause of impending paradoxical embolism

Thrombolysis for concomitant acute stroke and pulmonary embolism

Concomitant acute stroke, pulmonary and myocardial infarction due to in-transient thrombus across a patent foramen ovale

Simultaneous multifocal paradoxical embolism in an elderly patient with patent foramen ovale: A case report

Stroke associated with pulmonary embolism after air travel

A descriptive literature review of presentation, treatment and prognosis of high-risk PE and acute ischemic stroke

Massive pulmonary thromboembolism and stroke

Concomitant submassive pulmonary embolism and paradoxical embolic stroke after a long flight: which is the optimal treatment?

Patent Foramen Ovale and the Risk of Cerebral Infarcts in Acute Pulmonary Embolism-A Prospective Observational Study

Acute inferior ST-segment elevation myocardial infarction and previous cryptogenic stroke caused by a paradoxical embolism with a concomitant pulmonary embolism

Patent foramen ovale and stroke in intermediaterisk pulmonary embolism

Patent foramen ovale increases the risk of acute ischemic stroke in patients with acute pulmonary embolism leading to right ventricular dysfunction

Silent cerebral infarcts in patients with pulmonary embolism and a patent foramen ovale: a prospective diffusionweighted MRI study

Patent foramen ovale: Unanswered questions

Patent foramen ovale with atrial septal aneurysm may contribute to white matter lesions in stroke patients

One of the largest prospective study evaluating the risk of stroke in patients with PFO and symptomatic PE suggesting the importance of paradoxical embolism

Guidelines for the Use of Echocardiography in the Evaluation of a Cardiac Source of Embolism

Routine echocardiography in the management of stroke and transient ischaemic attack: a systematic review and economic evaluation

Clinical utility of echocardiography in secondary ischemic stroke prevention

Importance of adequately performed Valsalva maneuver to detect patent foramen ovale during transesophageal echocardiography

Deep vein thrombosis and pulmonary embolism among patients with a cryptogenic stroke linked to patent foramen ovale-A review of the literature

Imaging characteristics of ischemic strokes related to patent foramen ovale

Embolic strokes of undetermined source: the case for a new clinical construct

Patent foramen ovale: innocent or guilty? Evidence from a prospective population-based study

Patent foramen ovale and cryptogenic stroke in older patients

Prevalence of patent foramen ovale in patients with stroke

Patent foramen ovale as a risk factor for cryptogenic stroke

Cryptogenic stroke and patent foramen ovale: clinical clues to paradoxical embolism

Neurologic complications of venous thromboembolism

Long-Term Outcomes of Patent Foramen Ovale Closure or Medical Therapy after Stroke

Patent Foramen Ovale Closure or Anticoagulation vs. Antiplatelets after Stroke

Patent Foramen Ovale Closure or Antiplatelet Therapy for Cryptogenic Stroke

This systematic review and meta-analysis concluded that in patients with PFO and cryptogenic stroke, transcatheter device closure decreases risk for recurrent stroke compared with medical therapy alone

May-thurner syndrome -Analysis of the group of the patients

May-Thurner syndrome: History of understanding and need for defining population prevalence

This article emphasizes that the contribution of MTS to the development of DVT is likely undervalued in the setting of other more easily recognizable risk factors and difficulties surrounding diagnosis of MTS

May-Thurner syndrome in patients with cryptogenic stroke and patent foramen ovale: an important clinical association

Use of Magnetic Resonance Venography in Screening Patients With Cryptogenic Stroke for May-Thurner Syndrome

COVID-19 Map -Johns Hopkins Coronavirus Resource Center

Diagnosis, management, and pathophysiology of arterial and venous thrombosis in COVID-19

Incidence of thrombotic complications in critically ill ICU patients with COVID-19

Stroke as a neurological complication of COVID-19: A systematic review and meta-analysis of incidence, outcomes and predictors: Stroke and COVID-19

COVID-19-Related Stroke

Malignancies, prothrombotic mutations, and the risk of venous thrombosis

The mechanisms of cancerassociated thrombosis

Cancer-associated thrombosis: An overview of mechanisms, risk factors, and treatment. Cancers

Risk of arterial thromboembolism in patients with cancer

Patients with cerebral infarcts secondary to Trousseau syndrome usually have a more severe neurologic deficit at the onset of stroke and worse clinical outomes

Bilateral cerebral embolism as a characteristic feature of patients with Trousseau syndrome

Three-Territory DWI acute infarcts: Diagnostic value in cancer-Associated hypercoagulation stroke (trousseau syndrome)

Three territory sign: An MRI marker of malignancy-related ischemic stroke (Trousseau syndrome)

Cerebral infarction associated with benign mucin-producing adenomyosis: Report of two cases

Epidemiology of cancer-related venous thromboembolism

Risk of venous thromboembolism in patients with cancer: A systematic review and metaanalysis

Podoplanin expression in primary brain tumors induces platelet aggregation and increases risk of venous thromboembolism

Venous thromboembolism in brain tumors: Risk factors, molecular mechanisms, and clinical challenges

Combination of isocitrate dehydrogenase 1 (IDH1) mutation and podoplanin expression in brain tumors identifies patients at high or low risk of venous thromboembolism

The risk of venous thromboembolism is increased throughout the course of malignant glioma: An evidence-based review

Venous thromboembolism and survival in patients with high-grade glioma

ABO Blood Group is a potent risk factor for venous thromboembolism in patients with malignant gliomas. Cancer

Epidemiology of venous thromboembolism in 9489 patients with malignant glioma

Syncope in patients with pulmonary embolism: comparison between patients with syncope as the presenting symptom of pulmonary embolism and patients with pulmonary embolism without syncope

The Bezold-Jarisch reflex revisited: clinical implications of inhibitory reflexes originating in the heart

The Bezold-Jarisch reflex. A historical perspective of cardiopulmonary reflexes

Prognostic factors for pulmonary embolism: the prep study, a prospective multicenter cohort study

Combinations of prognostic tools for identification of high-risk normotensive patients with acute symptomatic pulmonary embolism

Identification of intermediate-risk patients with acute symptomatic pulmonary embolism

Comparison of risk assessment strategies for not-high-risk pulmonary embolism

Syncope as a presentation of acute pulmonary embolism

Value of syncope in patients with high-to-intermediate risk pulmonary artery embolism

Risk stratification and clinical outcomes in patients with acute pulmonary embolism

Syncope in acute pulmonary embolism

Prognostic value of syncope in the presentation of pulmonary embolism

Correlates of syncope in patients with acute pulmonary thromboembolism

Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER)

In this meta-analysis, the authors described various studies which found the association between syncope and PE versus those which didn't. Syncope had shown a higher prevalence of hemodynamic instability

Diagnostic and prognostic value of factors associated with pulmonary thromboembolism. Study of 70 autopsy cases

Factors associated with correct antemortem diagnosis of major pulmonary embolism

Prospective evaluation of patients with syncope: a population-based study

Prevalence of pulmonary embolism in patients with isolated syncope in the emergency department: the PEEPS multicenter prospective cohort study. Pulmonary embolism

Syncope in pulmonary embolism: a retrospective cohort study

Computed tomographic pulmonary angiography and prognostic significance in patients with acute pulmonary embolism

In-hospital and long-term outcome after submassive and massive pulmonary embolism submitted to thrombolytic therapy

Sudden loss of consciousness, dyspnea, and hypoxemia in a previously healthy young man

Pulmonary embolism presenting as seizures

Pulmonary thromboembolism presenting as epileptiform generalized seizure

Seizure as a presentation of pulmonary embolism

s10072-020-04275-y. A literature review of 258 articles analyzing pathophysiology, clinical presentation, treatment, and outcomes for patients with concomitant seizure and pulmonary embolism

Seizure and Pulmonary Embolism: A Differential That Can Save a Life. Case Rep Pulmonol

Pulmonary embolism as a cause of seizure

Post-thrombotic syndrome: a clinical review

Painful manifestations of the sequelae of phlebitis

Femoral Neuropathy: A Rare Presentation of Retroperitoneal Hematoma with Review of Literature

Femoral Neuropathy Following Transfemoral Neuroendovascular Procedures. An Analysis of a Prospective Registry

Peroneal nerve palsy caused by thrombosis of crural veins

Peroneal nerve palsy due to thrombosis of a crural vein in a healthy young woman

A Rare Cause of Compression of the Ulnar Nerve Neuritis: Deep Vein Thrombosis

Acute carpal tunnel syndrome resulting from haemorrhage into the carpal tunnel in a patient on warfarin

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations